Wide Ranks

ATHA

Athira Pharma, Inc.

0.6530

Top Statistics
Market Cap 25 M Forward PE -0.4006 Revenue Growth 0.00 %
Current Ratio 3.97 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.5110 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 91 M Total Cash Per Share 2.39 Total Debt 1 M
Total Debt To Equity 1.69 Current Ratio 3.97 Book Value Per Share 3.41
All Measures
Short Ratio 274.00 % Message Board Id finmb_266015004 Shares Short Prior Month 1 M
Return On Equity -0.8457 City Bothell Uuid bcfbfaea-5231-3987-ba3c-d263d037ec62
Previous Close 0.6200 First Trade Date Epoch Utc 1 B Book Value 3.41
Beta 2.83 Total Debt 1 M Volume 401698
Price To Book 0.1914 Fifty Two Week Low 0.4120 Total Cash Per Share 2.39
Shares Short Previous Month Date 1 B Target Median Price 0.5500 Audit Risk 8
Max Age 86400 Sand P52 Week Change 0.3133 Target Mean Price 0.5500
Net Income To Common -113451000 Short Percent Of Float 0.0576 Implied Shares Outstanding 38 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 413960
Average Volume10days 413960 Total Cash 91 M Next Fiscal Year End 1 B
Held Percent Insiders 0.0195 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Share Holder Rights Risk 8 Regular Market Previous Close 0.6200
Target Low Price 0.5000 Gmt Off Set Milliseconds -18000000 Fifty Day Average 0.5336
Open 0.6100 Free Cashflow -68054376 State WA
Dividend Yield 0.00 % Return On Assets -0.4753 Time Zone Short Name EST
Board Risk 6 Trailing Eps -2.84 Day Low 0.6100
Address1 18706 North Creek Parkway Shares Outstanding 38 M Compensation Risk 8
Price Hint 4 Target High Price 0.6000 Website https://www.athira.com
52 Week Change -0.5465 Average Volume 5 M Forward Eps -1.63
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 347.20 %
Is_sp_500 False Regular Market Day High 0.6700 Profit Margins 0.00 %
Debt To Equity 1.69 Fifty Two Week High 4.30 Day High 0.6700
Shares Short 1 M Regular Market Open 0.6100 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.0405
Operating Cashflow -98411000 Currency USD Time Zone Full Name America/New_York
Market Cap 25 M Is_nasdaq_100 False Zip 98011
Quote Type EQUITY Industry Biotechnology Long Name Athira Pharma, Inc.
Overall Risk 7 Regular Market Day Low 0.6100 Held Percent Institutions 0.6214
Current Price 0.6530 Address2 Suite 104 Enterprise To Ebitda 0.5110
Financial Currency USD Current Ratio 3.97 Industry Disp Biotechnology
Number Of Analyst Opinions 2 Country United States Float Shares 26 M
Two Hundred Day Average 2.12 Governance Epoch Date 1 B Enterprise Value -61532468
Forward PE -0.4006 Regular Market Volume 401698 Ebitda -120426000
Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation.

Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.

The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis.

In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton.

The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019.

Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.